Published January 2021 | Version v1
Journal article

Description and evaluation of a new volumetric-modulated arc therapy plan complexity metric

  • 1. Department of Radiation Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041 (China)
  • 2. Department of Radiotherapy, Yantai Yuhuangding Hospital, Qingdao University School of Medicine, Yantai, Shandong, 264000 (China)
  • 3. Academy of Medical Engineering and Translational Medicine, Tianjin University, Tianjin, 300072 (China)
  • 4. Department of Oncology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011 (China)

Description

This study describes a new plan complexity metric for volumetric-modulated arc therapy (VMAT) and evaluates the relationship of this metric with the VMAT dosimetric accuracy. The new modulation complexity score for VMAT (NMCSv) that is based on the aperture shape and multi-leaf collimator (MLC) leaf travel is described. Its performance is evaluated through correlation and receiver operating characteristic (ROC) analyses with patient-specific gamma passing rates using 2 3-dimensional diode arrays. For comparison, the following metrics are evaluated using the same correlation analyses: average field width, average leaf travel, modulation complexity score, and leaf travel modulation complexity score. Spearman's rank correlation analysis is performed to examine any relationships between the complexity metrics and the patient-specific gamma passing rates. ROC curves are used to assess the performance of the plan metrics using a gamma passing rate of 3%/3 mm criterion with a 95% tolerance level. In both the diode arrays, the gamma passing rates (3%/3 mm and 2%/2 mm) for patient-specific dosimetric verification of VMAT plans are moderately or weakly correlated to all the complexity metrics. NMCSv demonstrates the highest correlation with the passing rates (r = 0.652, p < 0.001 for Delta4 and r = 0.499, p < 0.001 for ArcCheck) and the highest area under the curve value (0.809, p < 0.01 for Delta4 and 0.734, p < 0.01 for ArcCheck). While using the Delta4 system, NMCSv exhibits an excellent classification performance with area under the curves of 0.926 (sensitivity: 0.913; specificity: 0.860; p < 0.01) and 0.918 (sensitivity: 0.943; specificity: 0.720; p < 0.01) for rectal and cervical cancer plans, respectively. NMCSv as a novel potential clinical plan complexity metric is moderately correlated with the gamma passing rate. It demonstrates the best performance with respect to distinguishing the dosimetric accuracy of VMAT plans among the evaluated metrics. The classification performance of complexity metrics can be affected by various dosimetry verification devices and treatment sites.

Availability note (English)

Available from http://dx.doi.org/10.1016/j.meddos.2020.11.004

Additional details

Identifiers

DOI
10.1016/j.meddos.2020.11.004;
PII
S0958394720301606;

Publishing Information

Journal Title
Medical Dosimetry
Journal Volume
46
Journal Issue
2
Journal Page Range
p. 188-194
ISSN
0958-3947

Optional Information

Copyright
Copyright (c) 2020 American Association of Medical Dosimetrists. Published by Elsevier Inc. All rights reserved.